InnoModels Biotechnology is committed to advancing innovation in the biomedical field, and its iHuPDX (Individualized Human Patient-Derived Xenograft) technology is an outstanding example of the company's commitment to personalized medicine. iHuPDX technology brings a new perspective to cancer research and treatment, providing more precise and personalized solutions for medical research and drug development. The introduction of iHuPDX technology brings a new perspective to cancer research and treatment, and provides a more precise and personalized solution for medical research and drug development.
Introduction of iHuPDX Technology
iHuPDX technology is a xenotransplantation technology based on patient's individual tumor cells, aiming to establish a more realistic and individualized cancer model. By collecting cancer tissue samples from patients and transplanting them into animals such as mice, individualized transplanted tumors are formed, thus providing a tumor model that is closer to the actual situation of the patient.
Key advantages of the technology
1. Individualized disease model:
The iHuPDX technology establishes a highly individualized disease model based on an individual patient's tumor cells. This helps to provide a more comprehensive understanding of a patient's tumor characteristics and provides important support for precision medicine.

2. Drug response prediction:
Due to the highly individualized nature of the model, iHuPDX technology can be used to test the response of different drugs to a specific patient's tumor. This provides a powerful tool for the development of personalized treatment plans and is expected to improve the success rate of treatment.
3. New perspectives in cancer research:
The iHuPDX technology enables researchers to probe more deeply into the differences in tumor heterogeneity between different patients. This helps reveal the diversity of cancers and provides important information for the development of individualized treatment strategies.
Future Outlook
InnoModels Biotechnology is confident about the future of iHuPDX technology. As biomedical research continues to deepen and technology continues to innovate, iHuPDX is expected to play an even more important role in the field of personalized medicine. In the future, we can expect to see more research results and application scenarios related to iHuPDX technology.
Conclusion
The iHuPDX technology of InnoModels Biotechnology is an important innovation in the field of personalized medicine. By providing highly individualized tumor models for medical research and drug development, iHuPDX opens up new possibilities for precision cancer treatment. InnoModels Biotechnology will continue to work to advance this technology and provide more effective treatment options for patients.